Gyre Therapeutics, Inc.
GYRE
$8.52
-$0.29-3.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 99.90% | -71.73% | 90.39% | 235.65% | -2,802.80% |
| Total Depreciation and Amortization | 52.92% | 124.75% | -25.16% | 48.60% | 172.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.27% | -54.15% | -39.06% | 2.02% | 1,026.43% |
| Change in Net Operating Assets | -135.56% | -173.71% | -1,667.43% | -218.32% | 291.34% |
| Cash from Operations | -182.08% | -77.24% | -221.18% | -72.31% | 588.44% |
| Capital Expenditure | 102.80% | 64.89% | 41.22% | 86.74% | -21.71% |
| Sale of Property, Plant, and Equipment | -17.37% | -101.38% | 62.69% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -57.53% | 55.42% | -23.25% | -19.18% | -286.28% |
| Cash from Investing | -249.66% | 55.80% | -2.76% | 5.60% | 215.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -61.44% | -- | -- | -- | 2,016.85% |
| Foreign Exchange rate Adjustments | -210.39% | -38.01% | 91.33% | -123.00% | 124.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.55% | -109.82% | -209.82% | -225.43% | 378.00% |